Commit To Purchase Optimer Pharmaceuticals At $10, Earn 36.5% Annualized

Investors eyeing a purchase of Optimer Pharmaceuticals Inc ( OPTR) shares, but tentative about paying the going market price of $14.16/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $10 strike, which has a bid at the time of this writing of 30 cents. Collecting that bid as the premium represents a 3% return against the $10 commitment, or a 36.5% annualized rate of return (at Stock Options Channel we call this the YieldBoost).

START SLIDESHOW:
Top YieldBoost Puts of the S&P 500 »

Selling a put does not give an investor access to OPTR's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $10 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked). So unless Optimer Pharmaceuticals Inc sees its shares fall 29.4% and the contract is exercised (resulting in a cost basis of $9.70 per share before broker commissions, subtracting the 30 cents from $10), the only upside to the put seller is from collecting that premium for the 36.5% annualized rate of return.

Below is a chart showing the trailing twelve month trading history for Optimer Pharmaceuticals Inc, and highlighting in green where the $10 strike is located relative to that history:

If you liked this article you might like

The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio

Comcast, Cubist Jump Pre-market Amid Cautious Trading

Morning Briefing: 10 Things You Should Know

Cubist Becomes Dominant Antibiotic Seller With Optimer, Trius Buys

5 Stocks Poised for Breakouts